JP2002525066A5 - - Google Patents

Download PDF

Info

Publication number
JP2002525066A5
JP2002525066A5 JP2000570351A JP2000570351A JP2002525066A5 JP 2002525066 A5 JP2002525066 A5 JP 2002525066A5 JP 2000570351 A JP2000570351 A JP 2000570351A JP 2000570351 A JP2000570351 A JP 2000570351A JP 2002525066 A5 JP2002525066 A5 JP 2002525066A5
Authority
JP
Japan
Prior art keywords
nucleic acid
pna
transport
nls
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000570351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002525066A (ja
Filing date
Publication date
Priority claimed from SE9803099A external-priority patent/SE9803099D0/xx
Application filed filed Critical
Publication of JP2002525066A publication Critical patent/JP2002525066A/ja
Publication of JP2002525066A5 publication Critical patent/JP2002525066A5/ja
Pending legal-status Critical Current

Links

Images

JP2000570351A 1998-09-13 1999-03-15 核酸の特異的な細胞の局在化のための転写法 Pending JP2002525066A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9803099A SE9803099D0 (sv) 1998-09-13 1998-09-13 Nucleic acid transfer
SE9803099-2 1998-09-13
PCT/SE1999/000398 WO2000015824A1 (en) 1998-09-13 1999-03-15 Transfer method for specific cellular localisation of nucleic acids

Publications (2)

Publication Number Publication Date
JP2002525066A JP2002525066A (ja) 2002-08-13
JP2002525066A5 true JP2002525066A5 (cg-RX-API-DMAC7.html) 2006-08-17

Family

ID=20412578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000570351A Pending JP2002525066A (ja) 1998-09-13 1999-03-15 核酸の特異的な細胞の局在化のための転写法

Country Status (9)

Country Link
US (1) US6720310B1 (cg-RX-API-DMAC7.html)
EP (1) EP1114172B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002525066A (cg-RX-API-DMAC7.html)
AT (1) ATE435918T1 (cg-RX-API-DMAC7.html)
AU (1) AU3178499A (cg-RX-API-DMAC7.html)
DE (1) DE69941089D1 (cg-RX-API-DMAC7.html)
DK (1) DK1114172T3 (cg-RX-API-DMAC7.html)
SE (1) SE9803099D0 (cg-RX-API-DMAC7.html)
WO (1) WO2000015824A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803099D0 (sv) 1998-09-13 1998-09-13 Karolinska Innovations Ab Nucleic acid transfer
US6312956B1 (en) * 1999-10-01 2001-11-06 Vanderbilt University Nuclear targeted peptide nucleic acid oligomer
JP2003514564A (ja) * 1999-11-24 2003-04-22 エムシーエス マイクロ キャリア システムズ ゲーエムベーハー 核局在化シグナルまたはタンパク質導入領域の多量体を含むポリペプチド、および分子を細胞内へ移入するためのその使用法
KR100374050B1 (ko) * 2000-07-26 2003-03-03 최수영 세포침투성 융합단백질, 이를 코딩하는 재조합폴리뉴클레오타이드 및 발현벡터
KR100420798B1 (ko) 2001-02-10 2004-03-02 (주)알에이싸이언스 펩타이드 벡터
SE0200531D0 (sv) * 2002-02-22 2002-02-22 Avaris Ab Novel biomolecular complexes, method for their production and use
SE0201234D0 (sv) * 2002-04-24 2002-04-24 Avaris Ab Transfer complex with added functionality and methods for its use
WO2004028562A2 (de) * 2002-09-23 2004-04-08 Mologen Ag Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
WO2005052166A1 (en) * 2003-11-29 2005-06-09 Young-Jin Chae Recombinant peptide vector comprising the gene for treatment for autoimmune diseases.
EP1841867A1 (en) 2005-01-24 2007-10-10 Avaris AB COMPLEX CONTAINING SiRNA, ShRNA OR ANTISENSE MOLECULE AND FUNCTIONAL ENTITY, FOR IMPROVED SPECIFICITY AND DELIVERY
US7795380B2 (en) * 2006-06-02 2010-09-14 University Of Iowa Research Foundation Compositions and methods for nucleic acid delivery
EP1900820A1 (en) * 2006-09-13 2008-03-19 Amaxa AG Nuclear transport agent and method for producing said agent
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CZ202030A3 (cs) * 2020-01-20 2021-04-14 PortalGene s.r.o. Způsob úpravy molekuly nukleové kyseliny pro usnadění jejího přenosu do hostitelských buněk a upravená molekula nukleové kyseliny

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4274149A (en) 1980-02-19 1981-06-16 Flanagan Charles E Binocular device for displaying elapsed time in the field of view
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5265003A (en) 1990-07-25 1993-11-23 Power Trends Miniaturized switching power supply with programmed level gate drive
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5641625A (en) 1992-05-22 1997-06-24 Isis Pharmaceuticals, Inc. Cleaving double-stranded DNA with peptide nucleic acids
JP2823959B2 (ja) * 1991-10-24 1998-11-11 アイシス・ファーマシューティカルス・インコーポレーテッド 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
AU682308C (en) * 1992-04-03 2006-08-17 Regents Of The University Of California, The Self-assembling polynucleotide delivery system
EP0804456B1 (en) 1994-10-06 2002-08-21 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
WO1996040961A1 (en) * 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
JP2001516562A (ja) * 1997-09-18 2001-10-02 ジーン セラピー システムズ インコーポレーテッド ペプチド核酸コンジュゲートを用いたdnaの化学修飾
SE9803099D0 (sv) 1998-09-13 1998-09-13 Karolinska Innovations Ab Nucleic acid transfer
US6312956B1 (en) * 1999-10-01 2001-11-06 Vanderbilt University Nuclear targeted peptide nucleic acid oligomer

Similar Documents

Publication Publication Date Title
US6720310B1 (en) Transfer method for specific cellular localization of nucleic acids
US11667903B2 (en) Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/CAS9
Lin et al. Tissue-specific mRNA delivery and prime editing with peptide–ionizable lipid nanoparticles
Kauffman et al. Synthetic molecular evolution of hybrid cell penetrating peptides
US11767528B2 (en) Targeted trans-splicing using CRISPR/Cas13
US20240043851A1 (en) Non-toxic cas9 enzyme and application thereof
KR102302679B1 (ko) 가이드 rna 및 엔도뉴클레아제를 유효성분으로 포함하는 암 치료용 약학적 조성물
CN109475646A (zh) 用于crispr/cas成分的脂质纳米颗粒制剂
WO2023102329A2 (en) Effector proteins and uses thereof
Min et al. A composite gene delivery system consisting of polyethylenimine and an amphipathic peptide KALA
Unciti-Broceta et al. The use of solid supports to generate nucleic acid carriers
Greitens et al. The intracellular visualization of exogenous DNA in fluorescence microscopy
Min et al. Gene delivery using a derivative of the protein transduction domain peptide, K-Antp
CN114901303A (zh) 修饰的核酸内切酶和相关方法
CN1339068A (zh) 转移核酸通过核被膜的细胞转运系统的用途
Maity et al. Intrinsically disordered Ku protein-derived cell-penetrating peptides
US20250302993A1 (en) Enzyme, complex, recombinant vector, therapeutic agent for genetic disorder, and polynucleotide
WO2024107665A1 (en) Effector proteins, compositions, systems and methods of use thereof
WO2024006824A2 (en) Effector proteins, compositions, systems and methods of use thereof
WO2023220570A2 (en) Engineered cas-phi proteins and uses thereof
EP4423263A2 (en) Effector proteins, compositions, systems, devices, kits and methods of use thereof
Maze et al. CFTR and dystrophin encoding plasmids carrying both luciferase reporter gene, nuclear import specific sequences and triple helix sites
Maloshenok et al. Visualizing the Nucleome Using the CRISPR–Cas9 System: From in vitro to in vivo
Shalaby Development of Non-Viral Vectors for Neuronal-Targeting of Crispr as a Therapeutic Strategy for Neurological Disorders
WO2024148303A1 (en) Rna-directed protease systems and uses thereof